• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Galectin Therapeutics (GALT)

Common Shares
Sell: $1.29|Buy: $1.34|Change: 0.07 (-5.11%)

Open 

$1.40

Previous close 

$1.37

Trade high 

$1.40

Volume 

77,324

Year high 

$3.62

Year low 

$0.72604

Dividend yield 

–

Market capitalisation 

$82.13 mn

P/E ratio 

–

ISIN 

US3632252025

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Performance 01/05/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Galectin Therapeutics- 5.11
More...

Company profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.